Difference in Days of Mechanical Ventilation in Prone Position Less than 48 Hours Compared to More than 48 Hours in Critical Patients with Sdra and Covid-19
Journal Title: International Journal Of Medical Science And Clinical Research Studies - Year 2022, Vol 2, Issue 08
Abstract
Introduction:TheCOVID 19 pandemic has come to change paradigms in terms of ventilatory support measures worldwide, prone ventilation was shown to decrease mortality in patients with ARDS. Objective:To identify the difference in days of mechanical ventilation of patients with respiratory failure by COVID-19 In the Intensive Care Unit with prone position for 48hours compared to>48hours.Material and methods: We evaluated all patients admitted to the Intensive Care Unit of UMAE Hospital No. 1 de Especialidades del Bajío, who required mechanical ventilation and prone position for refractory acute respiratory failure due to SARS-CoV-2 infection, we identified those in prone position for48hours versus > 48hours(h), and we evaluated the difference in days of mechanical ventilation between the two groups, concluding who maintainedmore days of mechanical ventilation. Results: Statistical significance was found only for the following variables: days of mechanical ventilation (p=<0.001), days of ICU stay (p=0.04), time in prone position (p=0.001) andPaO2/FiO2 ratioafter maintaining prone position(p=<0.001).Conclusion: The improvement in the oxygenation index in prone position >48 h is greater compared to those who remained 48 h, however, the time (days) under mechanical ventilation was less in the 48 h group; complications hadno impact on the time in prone position.
Authors and Affiliations
Ma. Natalia Gómez-González, Víctor González-Torres, Carlos Jiménez-Correa,Pedro Luis González-Carrillo
Keywords
Related Articles
- EP ID EP733098
- DOI 10.47191/ijmscrs/v2-i8-19
- Views 76
- Downloads 0
Pyogenic Liver Abscess
They predominate between the fifth and sixth decade of life, due to the higherincidence of neoplasms and complex biliary diseases, with higher incidence incountries with temperate climate. Most ar...
Aducanumab Opinion
Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD)but many uncertainties remain regarding both efficacy and safety. Of paramount concern areassociated...
Treatment of Pulmonary Sarcoidosis Using Allogenic Bone Marrow-Derived Mesenchymal Stem Cell Therapy is Safe: A Case Report
Mesenchymal stem cells have a proven potent immunomodulatory effect both in vitro and in vivo. We report a case of a 67-year-old male patient, first diagnosed with sarcoidosis in 2005, that responded well clinically and...
Dental Age Estimation in Down Syndrome Children, Using Schour-Massler and the Blenkin-Taylor Method in Jember Region
Background: Dental age estimation plays a vital role in today's medical world. There are various methods for determining the approximate age of a person. Dental age estimation seen from the growth of the...
Public Awareness of Depression – An Informal Clinical Study
The real challenge regards depression is the barriers associated with its diagnosis and treatment. These barriers are present due to the stigma associated with depression, as many individuals do not consider depression d...